[{"orgOrder":0,"company":"Bracco","sponsor":"GUERBET","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Neurology","graph2":"Phase III","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bracco \/ Bracco","highestDevelopmentStatusID":"10","companyTruncated":"Bracco \/ Bracco"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Precision For Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compounds","year":"2020","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Blue Earth Diagnostics \/ Precision For Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Precision For Medicine"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Human PSMA-7.3 (18F)","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Precision For Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compounds","year":"2020","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Blue Earth Diagnostics \/ Precision For Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Precision For Medicine"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compounds","year":"2022","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Blue Earth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Blue Earth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Blue Earth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Blue Earth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Blue Earth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compounds","year":"2020","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compounds","year":"2023","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Bracco","sponsor":"Bracco","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Rubidium-82","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bracco \/ Bracco","highestDevelopmentStatusID":"11","companyTruncated":"Bracco \/ Bracco"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Aixial Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compounds","year":"2024","type":"Inapplicable","leadProduct":"18-F Flotufolastat","moa":"PSMA","graph1":"Oncology","graph2":"Phase IV","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Aixial Group","highestDevelopmentStatusID":"11","companyTruncated":"Blue Earth Diagnostics \/ Aixial Group"},{"orgOrder":0,"company":"Bracco","sponsor":"Bracco","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gadopiclenol","moa":"gadolinium derivatives (principally for diagnostic use)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ Bracco","highestDevelopmentStatusID":"10","companyTruncated":"Bracco \/ Bracco"},{"orgOrder":0,"company":"Bracco","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bracco \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bracco \/ Inapplicable"},{"orgOrder":0,"company":"Bracco","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BR55","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Bracco \/ National Institutes of Health"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compounds","year":"2024","type":"Inapplicable","leadProduct":"18-F rhPSMA-7.3","moa":"PSMA","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"PSI CRO","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ PSI CRO","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ PSI CRO"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Blue Earth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"177-Lu rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Therapeutics \/ Blue Earth Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Blue Earth Therapeutics"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compounds","year":"2025","type":"Inapplicable","leadProduct":"177-Lu-rhPSMA-10.1","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bracco","sponsor":"Bracco","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gadolinium","moa":"Ribonucleoside-diphosphate reductase RR1 | Thioredoxin reductase 1","graph1":"Oncology","graph2":"Phase I","graph3":"Bracco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bracco \/ Bracco","highestDevelopmentStatusID":"6","companyTruncated":"Bracco \/ Bracco"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compounds","year":"2023","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase I","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"6","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu rhPSMA","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Blue Earth Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Blue Earth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"225-Ac rhPSMA-10.1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Therapeutics \/ Blue Earth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Blue Earth Therapeutics \/ Blue Earth Therapeutics"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"225-Ac rhPSMA-10.1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Blue Earth Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Blue Earth Therapeutics","sponsor":"University College London","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"225-Ac rhPSMA-10.1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Blue Earth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Therapeutics \/ University College London","highestDevelopmentStatusID":"4","companyTruncated":"Blue Earth Therapeutics \/ University College London"}]
Find Clinical Drug Pipeline Developments & Deals by Bracco
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
